CPA
BBIO icon

Capital Performance Advisors’s BridgeBio Pharma BBIO Stock Holding History

Capital Performance Advisors’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-222
Closed -$5.65K – 442
2024
Q3 		$5.65K Buy
+222
New +$5.83K ﹤0.01% 1064

Other funds holding BBIO

KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Capital Performance Advisors's BBIO Position: Q4 2024 in Review

Capital Performance Advisors sold out of BridgeBio Pharma (BBIO) in Q4 2024, closing a stake of 222 shares — an estimated $5.65K sold.

Capital Performance Advisors first reported a position in BBIO in Q3 2024 and held it in 1 quarter. The position peaked at $5.65K in Q3 2024. 263 funds tracked by Wall St. Rank hold BBIO as of Q4 2024.

  • Capital Performance Advisors reported no remaining BridgeBio Pharma position as of Q4 2024 after selling out during the quarter.
  • Capital Performance Advisors sold 222 BridgeBio Pharma shares in Q4 2024, an estimated $5.65K.
  • Capital Performance Advisors first reported a position in BridgeBio Pharma in Q3 2024 and held it in 1 quarter.
  • Capital Performance Advisors's BridgeBio Pharma position peaked at $5.65K in Q3 2024.
  • 263 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q4 2024.

Based on Capital Performance Advisors's 13F filing for Q4 2024, filed 31 Jan 2025.